Eli Lilly and Company (NYSE:LLY) Stock Holdings Raised by Jacobs & Co. CA

Jacobs & Co. CA grew its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 35.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 29,391 shares of the company's stock after purchasing an additional 7,646 shares during the period. Eli Lilly and Company comprises about 2.3% of Jacobs & Co. CA's portfolio, making the stock its 8th largest position. Jacobs & Co. CA's holdings in Eli Lilly and Company were worth $22,690,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in LLY. CWA Asset Management Group LLC boosted its holdings in shares of Eli Lilly and Company by 11.9% in the 4th quarter. CWA Asset Management Group LLC now owns 6,794 shares of the company's stock worth $5,245,000 after buying an additional 724 shares during the last quarter. M&T Bank Corp raised its position in Eli Lilly and Company by 0.7% in the third quarter. M&T Bank Corp now owns 266,822 shares of the company's stock worth $236,389,000 after acquiring an additional 1,867 shares during the period. Everence Capital Management Inc. boosted its stake in Eli Lilly and Company by 3.2% in the fourth quarter. Everence Capital Management Inc. now owns 22,340 shares of the company's stock valued at $17,246,000 after acquiring an additional 690 shares during the last quarter. Nordea Investment Management AB grew its position in shares of Eli Lilly and Company by 13.7% during the 4th quarter. Nordea Investment Management AB now owns 1,154,350 shares of the company's stock valued at $887,014,000 after acquiring an additional 138,835 shares during the period. Finally, Ables Iannone Moore & Associates Inc. bought a new stake in shares of Eli Lilly and Company in the 4th quarter worth approximately $899,000. 82.53% of the stock is owned by institutional investors.

Insider Activity

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 900 shares of Eli Lilly and Company stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $803.38, for a total value of $723,042.00. Following the transaction, the chief accounting officer now directly owns 5,480 shares of the company's stock, valued at $4,402,522.40. The trade was a 14.11 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.13% of the stock is owned by corporate insiders.

Eli Lilly and Company Price Performance

Shares of Eli Lilly and Company stock traded up $12.17 on Friday, hitting $799.39. 3,970,839 shares of the company traded hands, compared to its average volume of 3,126,156. Eli Lilly and Company has a 12-month low of $612.70 and a 12-month high of $972.53. The company has a current ratio of 1.27, a quick ratio of 0.97 and a debt-to-equity ratio of 2.03. The company has a market cap of $758.87 billion, a P/E ratio of 86.42, a P/E/G ratio of 2.99 and a beta of 0.41. The firm's 50-day simple moving average is $786.08 and its 200 day simple moving average is $860.02.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings data on Wednesday, October 30th. The company reported $1.18 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.52 by ($0.34). The firm had revenue of $11.44 billion during the quarter, compared to analysts' expectations of $12.09 billion. Eli Lilly and Company had a return on equity of 71.08% and a net margin of 20.48%. Eli Lilly and Company's revenue for the quarter was up 20.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.10 earnings per share. Analysts expect that Eli Lilly and Company will post 13.18 earnings per share for the current fiscal year.

Eli Lilly and Company declared that its Board of Directors has approved a stock repurchase program on Monday, December 9th that permits the company to repurchase $15.00 billion in outstanding shares. This repurchase authorization permits the company to repurchase up to 2% of its shares through open market purchases. Shares repurchase programs are usually an indication that the company's leadership believes its shares are undervalued.

Eli Lilly and Company Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, March 10th. Stockholders of record on Friday, February 14th will be issued a $1.50 dividend. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.75%. This is a positive change from Eli Lilly and Company's previous quarterly dividend of $1.30. The ex-dividend date is Friday, February 14th. Eli Lilly and Company's payout ratio is presently 64.86%.

Analysts Set New Price Targets

Several equities analysts have weighed in on the company. Cantor Fitzgerald reissued an "overweight" rating and set a $885.00 price objective on shares of Eli Lilly and Company in a report on Monday, September 16th. StockNews.com upgraded Eli Lilly and Company from a "hold" rating to a "buy" rating in a research note on Wednesday, January 1st. JPMorgan Chase & Co. boosted their price objective on Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the company an "overweight" rating in a research note on Friday, September 13th. Bank of America reiterated a "buy" rating and set a $997.00 target price on shares of Eli Lilly and Company in a research report on Tuesday, December 10th. Finally, Deutsche Bank Aktiengesellschaft lowered their price target on shares of Eli Lilly and Company from $1,025.00 to $1,015.00 and set a "buy" rating on the stock in a research report on Monday, November 4th. Four research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $1,002.22.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.